Valuation: Pulmatrix Inc

Market Cap 5.55M 4.89M 4.63M 4.18M 7.88M 532M 7.98M 55.42M 21.33M 272M 20.85M 20.39M 872M P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 1.46M 1.29M 1.22M 1.1M 2.08M 140M 2.1M 14.61M 5.62M 71.74M 5.5M 5.38M 230M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.22%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 20/07/2024
Director TitleAgeSince
Director/Board Member 58 01/11/2019
Director/Board Member 57 23/06/2020
Director/Board Member 55 01/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
-8.33%+504.03% - - 5.69M
+4.16%-0.36%+49.37%+94.17% 71.53B
-0.19%+1.32%+37.20%+83.85% 60.12B
-1.51%+2.39%+9.10%+35.15% 48.85B
-0.05%+0.37%+41.54%+36.65% 44.28B
+0.38%+7.61%+339.53%+641.55% 43.83B
+0.18%+0.26%+7.41%+103.45% 41.53B
-0.67%+0.17%+7.60%+46.37% 30.13B
+4.77%+6.16%+36.77%+22.78% 27.98B
-1.29%-3.55%-20.74%+352.04% 25.25B
Average -0.26%+1.18%+56.42%+157.33% 43.72B
Weighted average by Cap. +0.80%+1.37%+60.93%+148.55%

Financials

2024 2025
Net sales 7.81M 6.87M 6.51M 5.88M 11.08M 748M 11.23M 77.92M 29.99M 383M 29.31M 28.67M 1.23B -
Net income -9.56M -8.42M -7.98M -7.2M -13.57M -917M -13.75M -95.42M -36.72M -469M -35.89M -35.11M -1.5B -5.16M -4.55M -4.31M -3.89M -7.33M -495M -7.42M -51.53M -19.83M -253M -19.38M -18.96M -811M
Net Debt -9.52M -8.38M -7.94M -7.17M -13.52M -913M -13.69M -95.04M -36.57M -467M -35.75M -34.97M -1.5B -4.09M -3.6M -3.41M -3.08M -5.8M -392M -5.88M -40.81M -15.7M -200M -15.35M -15.02M -642M
Logo Pulmatrix Inc
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
-